Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study

NCT02316470 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile

Interventions

BIOLOGICAL: VLA84
BIOLOGICAL: Placebo

Sponsor

Valneva Austria GmbH